Prognostic assessment in COPD without lung function: The B-AE-D indices

European Respiratory Journal

Volumn 47, Issue 6, 2016, Pages 1635-1644

  Boeck, Lucas ^a   Soriano, Joan B ^b   Brusse Keizer, Marjolein ^c   Blasi, Francesco ^d   Kostikas, Konstantinos ^e   Boersma, Wim ^f   Milenkovic, Branislava ^g,h   Louis, Renaud ⁱ   Lacoma, Alicia ^j   Djamin, Remco ^k   Aerts, Joachim ^k   Torres, Antoni ^l   Rohde, Gernot ^m   Welte, Tobias ⁿ   Martinez Camblor, Pablo ^o   Rakic, Janko ^a   Scherr, Andreas ^a   Koller, Michael ^p   Van Der Palen, Job ^c   Marin, Jose M ^q   Alfageme, Inmaculada ^r   Almagro, Pere ^s   Casanova, Ciro ^t   Esteban, Cristobal ^u   Soler Cataluña, Juan J ^v   De Torres, Juan P ^w   Miravitlles, Marc ^x   Celli, Bartolome R ^y   Tamm, Michael ^a   Stolz, Daiana ^a   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF THESSALY   (Greece)

^f Medical Centre Alkmaar   (Netherlands)

^g UNIVERSITY OF BELGRADE   (Serbia)

^h CLINICAL CENTER OF SERBIA   (Serbia)

ⁱ UNIVERSITY OF LIÈGE   (Belgium)

^j HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^k AMPHIA HOSPITAL   (Netherlands)

^l HOSPITAL CLÍNIC   (Spain)

^m MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

^p UNIVERSITY HOSPITAL BASEL   (Switzerland)

^q HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^r HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^s HOSPITAL MÚTUA DE TERRASSA   (Spain)

^t HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^u HOSPITAL DE GALDAKAO   (Spain)

^v HOSPITAL ARNAU DE VILANOVA   (Spain)

^w UNIVERSITY CLINIC OF NAVARRA   (Spain)

^x HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^y HARVARD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; GLYCOPEPTIDE; OXYGEN;

AGE; AGED; AIRWAY OBSTRUCTION; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EXERCISE; FEMALE; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; RISK ASSESSMENT; SMOKING; BLOOD; CHEMISTRY; FORCED EXPIRATORY VOLUME; INFLAMMATION; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

AGED; BODY MASS INDEX; DYSPNEA; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; GLYCOPEPTIDES; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; LUNG; MALE; MIDDLE AGED; MORTALITY; OXYGEN; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TREATMENT OUTCOME;

EID: 84973454470     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01485-2015     Document Type: Article

References (49)

1. Rosenbaum L, Lamas D. Facing a "slow-motion disaster" - the UN Meeting on noncommunicable diseases. N Engl J Med 2011; 365: 2345-2348.
2. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007; 370: 765-773.
3. Taraseviciene-Stewart L, Voelkel NF. Molecular pathogenesis of emphysema. J Clin Invest 2008; 118: 394-402.
4. Celli BR, Cote CG, Marín JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012.
5. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704-711.
6. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 1189-1195.
7. Celli BR, Marin JM, Cote CG, et al. Prognostic assessment of patients with COPD. Lancet 2009; 374: 1885-1887.
8. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-382.
9. Stolz D, Kostikas K, Blasi F, et al. Adrenomedullin refines mortality prediction by the BODE index in COPD: the "BODE-A" index. Eur Respir J 2014; 43: 397-408.
10. Stolz D, Meyer A, Rakic J, et al. Mortality risk prediction in COPD by a prognostic biomarker panel. Eur Respir J 2014; 44: 1557-1570.
11. Stolz D, Christ-Crain M, Bingisser R, et al. Antibiotic treatment of exacerbations of COPD. Chest 2007; 131: 9-19.
12. Marín JM, Alfageme I, Almagro P, et al. Multicomponent indices to predict survival in COPD: the COCOMICS study. Eur Respir J 2013; 42: 323-332.
13. Soler-Cataluña JJ, Martínez-García MA, Román, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925-931.
14. Alfageme I, Reyes N, Merino M, et al. The effect of airflow limitation on the cause of death in patients with COPD. Chronic Respir Dis 2010; 7: 135-145.
15. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 591-597.
16. Marín JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea. Am J Respir Crit Care Med 2010; 182: 325-331.
17. Almagro P, Calbo E, Ochoa de Echagüen A, et al. Mortality after hospitalization for COPD. Chest 2002; 121: 1441-1448.
18. Almagro P, Salvadó M, Garcia-Vidal C, et al. Recent improvement in long-term survival after a COPD hospitalisation. Thorax 2010; 65: 298-302.
19. Zuur-Telgen MC, Brusse-Keizer MG, Vandervalk PD, et al. Stable state MR-proadrenomedullin level is a strong predictor of mortality in COPD patients. Chest 2013; 145: 534-541.
20. Crapo RO, Casaburi R, Coates AL, et al. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117.
21. Brusasco V, Crapo R, Viegi G, et al. Coming together: the ATS/ERS consensus on clinical pulmonary function testing. Eur Respir J 2005; 26: 1-2.
22. Morgenthaler NG, Morgenthaler NG, Struck J, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119.
23. Morgenthaler NG, Struck J, Jochberger S, et al. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metabol 2008; 19: 43-49.
24. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: Suppl. 2, 398S-401S.
25. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-469.
26. Tibshirani R. Regression shrinkage and selection via the lasso. J R Stat Soc Series B Stat Methodol 1996; 58: 267-288.
27. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models. Epidemiology 2010; 21: 128-138.
28. Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 160: 1856-1861.
29. Hallin R, Gudmundsson G, Suppli Ulrik C, et al. Nutritional status and long-term mortality in hospitalised patients with chronic obstructive pulmonary disease (COPD). Respir Med 2007; 101: 1954-1960.
30. Rutten EPA, Calverley PMA, Casaburi R, et al. Changes in body composition in patients with chronic obstructive pulmonary disease: do they influence patient-related outcomes. Ann Nutr Metab 2013; 63: 239-247.
31. Schols A, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 157: 1791-1797.
32. Prescott E, Almdal T, Mikkelsen KL, et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 2002; 20: 539-544.
33. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation (World Health Organization technical report series 894). WHO, Geneva, 2000. Available from: www.who.int/nutrition/publications/obesity/WHO-TRS-894/en/
34. Connors AF, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996; 154: 959-967.
35. Groenewegen KH, Schols A, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459-467.
36. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013; 42: 636-646.
37. Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, et al. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103: 692-699.
38. Nishimura K, Izumi T, Tsukino M, et al. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434-1440.
39. Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54: 581-586.
40. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification. Am J Respir Crit Care Med 2012; 186: 975-981.
41. Cote CG, Dordelly LJ, Celli BR. Impact of COPD exacerbations on patient-centered outcomes. Chest 2007; 131: 696-704.
42. Raff H, Shinsako J, Keil LC, et al. Vasopressin, ACTH, and corticosteroids during hypercapnia and graded hypoxia in dogs. Am J Physiol 1983; 244: E453-E458.
43. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979; 236: F321-F332.
44. Raff H, Kane CW, Wood CE. Arginine vasopressin responses to hypoxia and hypercapnia in late-gestation fetal sheep. Am J Physiol 1991; 260: R1077-R1081.
45. Stolz D, Christ-Crain M, Morgenthaler NG, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007; 131: 1058-1067.
46. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
47. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-212.
48. Camiciottoli G, Bigazzi F, Bartolucci M, et al. BODE-index, modified BODE-index and ADO-score in chronic obstructive pulmonary disease: relationship with COPD phenotypes and CT lung density changes. COPD 2012; 9: 297-304.
49. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 2013; 1: 43-50.